SOFUSA Lymphatic Drug Delivery Platform
The Sofusa® Lymphatic Delivery System (S-LDS) inzira nyowani yekurapa yakagadzirirwa kuendesa mishonga inobaiwa yakananga mulymphatic uye systemic capillaries pazasi peepidermis kuburikidza neine proprietary microneedle uye microfluidics system.
Sofusa Lymphatic Delivery System tsananguro. Shanyira www.sofusa.com »
Pre-Clinical modhi inoratidza zvingangobatsira zve lymphatic kunanga neSofusa proprietary nano-draped microneedles.1
- > 40-kupeta kuwedzera kwehuwandu hwezvinodhaka mumalymph nodes vs subcutaneous jekiseni (SC) kana intravenous (IV) infusions.
- Yakavandudzwa bundu kupinda ne 1/10th dose
- Kuvandudza anti-tumor efficacy uye kuderedza metastases
Human Clinical Phase 1B RA kudzidza kuongorora intra-lymphatic delivery2
- 12-vhiki yakavhurika label kudzidza kunyoresa varwere vane mhinduro isina kukwana ku50mg vhiki nevhiki Enbrel® subcutaneous jekiseni (n=10)
- Varwere vekutanga vatatu vakapedza, 3mg vhiki nevhiki (25% yeSC dose)
- 36%/38% kuderedza muChirwere Chiitiko (DAS28 ESR/CRP)
- 80% kuderedza kuzvimba majoini kuverenga
- 77% kuvandudzwa muChiremba Global Assessment Score
Human Checkpoint POC zvidzidzo zvirikuenderera mberi neMayo Clinic
1) Walsh et al., "Nanotopography Inofambisa muVivo Transdermal Delivery… Nano Letters, ACSJCA, 2015
2) Mhedzisiro iAvhareji yevarwere vekutanga 3 (vakanyoresa zvishoma), Phase 1b chiratidzo-che-pfungwa yakavhurika label kudzidza kuongorora kuchengetedzeka uye kugona kwemutyairi weEnbrel® inopihwa varwere vane Rheumatoid arthritis vachishandisa Sofusa® DoseConnct®.